Matt Scholz is a co-founder of Oisin Biotechnologies, a longevity startup that is developing a proteome-lipid nanoparticle gene therapy platform. Their lead program is a senolytic gene therapy to target senescent cells.
Daniel Ives is the founder of Shift Bioscience, a longevity biotech company that targeting aging from mitochondrial DNA dysfunction and epigenetic screens.
Show Notes
Coming soon.